Made Scientific and Streamline Bio Launch AI-Driven Robotics for Cell Therapies

Made Scientific and Streamline Bio have announced a collaboration aimed at revolutionizing cell therapy manufacturing through advanced robotics. On October 6, 2025, the two companies revealed the successful initial validation of Streamline Bio’s AI-driven robotics platform in a live production environment for cell therapies at Made Scientific’s facility in Princeton, New Jersey.

This partnership is set to streamline the complex processes involved in cell and gene therapy (CGT) manufacturing. The companies are now focusing on integrating this technology into Good Manufacturing Practice (GMP) environments, which includes launching early-adopter programs and collaborating on the deployment of this fully automated solution for innovators in cell therapy.

Addressing Industry Challenges

Streamline Bio’s platform is designed to tackle significant challenges in the CGT sector, such as manufacturing complexity and the high costs associated with variable quality in cell therapies. Unlike traditional robotic automation systems that often require extensive infrastructure and are inflexible, Streamline Bio’s solution is purpose-built to adapt to the multi-step processes involved in cell therapy production.

This innovative platform can seamlessly integrate with existing equipment and protocols, minimizing the need for costly process alterations or custom configurations. By automating labor-intensive steps, it not only reduces the burden on operators but also mitigates human error, ultimately lowering costs and allowing skilled personnel to concentrate on higher-value activities. Furthermore, its digital-first design ensures full data traceability.

Next Steps and Future Impact

As the collaboration progresses, Made Scientific and Streamline Bio are preparing the robotic platform for GMP deployment using systems such as Miltenyi CliniMACS Prodigy, G-Rex, and Fresenius-Kabi LOVO. The successful validation of this fully robotic platform in a live manufacturing environment positions it for integration into Made Scientific’s GMP cleanrooms, showcasing its capacity to manage complex workflows efficiently.

Future studies will further evaluate additional operations and use cases, including automated analytical and quality control testing workflows. According to Rodney Rietze, Ph.D., President and CEO of Streamline Bio, “Today’s CGT processes are incredibly nuanced and complex. Streamline Bio’s robotic platform allows cell and gene therapy developers and manufacturers to respond with automation that’s not only smart and scalable but inherently adaptive.”

Syed T. Husain, Chairman and CEO of Made Scientific, expressed enthusiasm about the partnership, stating, “Streamline Bio is redefining manufacturing by offering an innovative and flexible platform aimed at making transformative therapies more accessible to patients.” The collaboration aims to significantly impact costs, process efficiency, product reproducibility, and the timeline for bringing emerging therapies to clinical use.

Both companies are committed to advancing the future of cell therapy manufacturing, leveraging cutting-edge technology to enhance accessibility and effectiveness in the treatment landscape.